Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cubicin

This page shows the latest Cubicin news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf

Meanwhile, Merck Sharp &Dohme ( MSD) also received an extension recommendation for Cubicin (daptomycin), an injectable antibiotic for adults and paediatric patients with staphylococcus aureus bacteraemia (SAB).

Latest news

  • Merck defeated in antibiotic patent case in US Merck defeated in antibiotic patent case in US

    Cubicin is an injectable antibiotic indicated for complicated skin and skin structure infections caused by Gram-positive bacteria, as well as bacteraemia caused by Staphylococcus aureus. ... Nevertheless, if Cubicin succumbs to generic competition early

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    Novartis' Cubicin (daptomycin) was backed for use in adults and paediatric patients with complicated skin and soft-tissue infections.

  • Merck hopes for another Keytruda with new immunotherapy deal Merck hopes for another Keytruda with new immunotherapy deal

    Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    The approval of Zerbaxa adds to Cubist's stable of antibiotics, which include $1bn-a-year blockbuster Cubicin (daptomycin) as well as recently-approved Sivextro (tedizolid phosphate) for acute bacterial skin ... The ruling opened the door for generic

  • UPDATE: Merck to acquire Cubist for $8.4bn UPDATE: Merck to acquire Cubist for $8.4bn

    Its main product is currently Cubicin (daptomycin for injection), which is approved for complicated skin and skin structure infections caused by certain bacteria and in Staphylococcus aureus infections of the bloodstream. ... According to the company's

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    Cubicin (daptomycin) is Cubist's leading product with net revenues of $256.7m for the third quarter of 2014.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Cubicin is also approved for the treatment of bacteraemia caused by MRSA and methicillin-susceptible Staphylococcus aureus (MSSA). ... Under this ruling, four out of five Cubist patents protecting Cubicin were invalidated.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Melinta names chief medical officer Melinta names chief medical officer

    She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company's immunology and ... Melinta's CEO Mary Szela said: "The extensive

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...

Quick links